Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in active material science, has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution to address these degradation drivers for pharmaceutical drugs, including oral solid dose glucagon-like peptide-1 (GLP-1), medical devices and more.

This new solution extends Aptar CSP Technologies’ 3-Phase Activ-Polymer technology into new use cases where a combination of humidity and oxidation can compromise the efficacy, safety, and shelf life of sensitive oral solid dose drugs, medical devices, implantable mesh devices, microarray patches and transdermal delivery systems.

“This launch reflects years of development, engineering excellence, and a deep understanding of our customers’ most pressing stability challenges,” said Badre Hammond, Vice President Commercial Operations and General Manager, Aptar CSP Technologies. “There has never been a singular, standalone active material aimed at protecting against both oxidation and moisture-related degradation at this level of precision across multiple platforms. We’re proud to offer a solution that is not only scientifically differentiated but can also be commercially validated.”

Aptar CSP’s new dual-active technology can be customized for a range of product formats and development stages, from early R&D to commercial launch. The technology can help support regulatory compliance and product protection across a variety of formats, aimed at helping companies meet strict International Council for Harmonization (ICH) stability requirements while maintaining performance and integrity of sensitive drug or device components.